TL;DR
This study investigates how specific mutations in the N-terminal fragment of apolipoprotein A-I (ApoA-I), known to cause amyloidosis, affect its aggregation pathway. The researchers found that while some mutations significantly accelerate aggregation, the overall mechanism of amyloid formation is complex and likely involves more than just increased aggregation propensity.
What Problem Does This Paper Address?
Apolipoprotein A-I (ApoA-I) is a key protein in high-density lipoproteins, crucial for cholesterol transport. Mutations in the ApoA-I gene are linked to various diseases, including familial hypercholesterolemia and systemic amyloidosis. In amyloidosis, specific fragments of ApoA-I, particularly the N-terminal 93-residue peptide ([1-93]ApoA-I), misfold and aggregate into amyloid fibrils, leading to tissue damage. While it's known that mutations can cause amyloidosis, the precise impact of these mutations on the aggregation kinetics and structural changes of the [1-93]ApoA-I fragment, especially those located within this fragment ("inside mutations"), remained largely uncharacterized. This paper aims to fill this gap by systematically studying the aggregation behavior of eight known pathogenic variants of [1-93]ApoA-I.
Methods
The researchers employed a multi-pronged approach to characterize the aggregation of wild-type and mutant [1-93]ApoA-I peptides:
- Recombinant Peptide Production: They produced eight pathogenic variants of [1-93]ApoA-I using site-directed mutagenesis. These peptides were expressed as glutathione S-transferase (GST) fusion proteins in bacteria to enhance stability and protect them from degradation.
- Mass Spectrometry (MS): Used to confirm the correct amino acid sequence and homogeneity of the recombinant peptides.
- Circular Dichroism (CD) Spectroscopy: Far-UV CD was used to assess the secondary structure of the peptides at different pH levels (neutral pH 7.0 and acidic pH 4.0), revealing structural transitions upon acidification.
- Light Scattering: Monitored the increase in turbidity at 350 nm to quantify the rate of aggregation at pH 4.0.
- Fourier Transform Infrared (FTIR) Spectroscopy: Analyzed the aggregated material to identify the presence of β-sheet structures, a hallmark of amyloid aggregates, by examining the amide I band.
- Atomic Force Microscopy (AFM): Visualized the morphology of the aggregates formed by the variants, providing insights into their size, shape, and arrangement.
- Computational Predictions: Utilized the Zyggregator method to predict aggregation-prone regions and the CamP method to estimate conformational fluctuations and protection factors for hydrogen exchange.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- pH-Dependent Structural Transition: Acidification (pH 4.0) induces a transition from a disordered state to an unstable α-helical conformation, which precedes aggregation into a cross-β structure.
- Differential Aggregation Kinetics: Not all mutations equally accelerate aggregation. Some mutations dramatically speed up the process, while others have little to no effect compared to the wild-type.
- Aggregation Propensity vs. Disease Severity: While increased aggregation propensity is a factor, it doesn't fully explain the disease mechanism. The study suggests a complex interplay between increased shedding of the amyloidogenic peptide and its aggregation rate.
- Structural Basis of Aggregation: The study links structural changes (α-helix formation upon acidification) to aggregation kinetics and the final β-sheet structure of the aggregates.
- Computational-Experimental Correlation: Predicted aggregation propensities using computational tools showed good agreement with experimentally determined aggregation rates, validating the predictive power of these methods.
Key Results
- Accelerated Aggregation: Two mutations (A70–72 and L90P) significantly accelerated the aggregation kinetics, with aggregation occurring rapidly within the measurement lag phase.
- Moderately Accelerated Aggregation: Three mutations (A60–71/VT, L75P, and W50R) showed a 2- to 3-fold increase in aggregation rate compared to the wild-type.
- No Significant Change: The remaining three mutations (L64P, L60R, and G26R) did not significantly alter the aggregation rate compared to the wild-type.
- β-Sheet Structure: FTIR analysis confirmed that the aggregates of all variants, including wild-type, displayed characteristic intermolecular β-sheet structures.
- Morphology: AFM revealed spheroidal structures, often forming clusters and filaments, but not mature fibrils within the 48-hour incubation period.
Limitations and Future Work
- In Vivo Relevance: The study was conducted in vitro. While it provides mechanistic insights, the direct translation to the complex in vivo environment, including interactions with lipids and other proteins, requires further investigation.
- "Outside Mutations": The study focused on "inside mutations" within the [1-93]ApoA-I fragment. The role of "outside mutations" in facilitating the release of this fragment is not directly addressed.
- Correlation with Disease Onset: While a correlation between aggregation propensity and age of onset was suggested for two specific variants, this correlation is not universally established for all mutations and requires more extensive clinical data.
- Future Directions: The authors suggest that further research should explore how natural ligands like phospholipids and cholesterol might influence peptide aggregation and prevent fibril formation. Investigating the role of mutations in enhancing the shedding of the amyloidogenic peptide is also a crucial next step.
Summary updated